Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
02 July 2019 | Story Leonie Bolleurs
Edwin Skhosana
Edwin Skhosana is working hard to become a successful and competent actuary one day. With him is his lecturer, Dr Michael von Maltitz.

Edwin Skhosana, an Actuarial Sciences student, was described by his lecturer, Dr Michael von Maltitz of the Department of Mathematical Statistics and Actuarial Science, as ‘very quiet’ in his Causal Inference class. 

This may sound like a compliment, but it’s not.

For Dr Von Maltitz, being quiet is definitely not encouraged – not with the new teaching methods applied in class.

“See, my class is all about engagement – getting the students to watch videos on the topics, read about the methods in question, and then come to class to grill me about things they don’t understand. This change in teaching method is extremely disconcerting for many Mathematical students, who have up until now only been taught in the ‘memorise-regurgitate’ form they had ever since the start of high school,” he explains.

Future success


“My goal is to get the students to a level of understanding where they can sit down with me or with an expert in the field and have a conversation about the Mathematical Statistics topics that I teach. This is a very difficult task in such a technical module, and few students ever feel comfortable enough to engage with me actively in class in this way,” Dr Von Maltitz points out. 

Edwin is working hard towards applying the skills and knowledge he has obtained at university to become a successful and competent actuary one day. 

An important turning point was when it dawned on him how the things discussed in class could find an important practical application in so many fields.  

“This suddenly drove a spontaneous fascination in my mind that led me to engage with Dr Von Maltitz,” the previously quiet Edwin explains.

And everything changed.

Desperate to learn

Dr Von Maltitz explains: “Edwin came to my office to ask some questions. The incredible thing was that he sat down, and a conversation about the Mathematics, the foundations, and the methods just flowed between us. I have seldom had such an insightful chat about my module with a student. It was like a cascade of information just fell into place for Edwin.”

Although he sometimes still experiences his studies as challenging and grapples to adapt to the various styles of lecturing from different lecturers, Edwin now has hope for his class in Causal Inference. 

“I think Dr Von Maltitz’s way of presenting in class is excellent. It is, however, hard to grasp if you are still anchored in the old way of cramming, because he wants you to understand and be able to apply what he teaches,” says Edwin.

“It was just wonderfully refreshing to see someone so desperate to learn something (rather than just wanting to get a degree), and then actually managing to turn around a bad semester mark into such a river of understanding,” Dr Von Maltitz concludes.

Dr Michael von Maltitz
Dr Micheal von Maltitz

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept